TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26727041

Group type: EXPERIMENTAL
Intervention: Metyrapone (500 mg twice daily)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Metyrapone
Number of subjects: 165
Study: 25523407

Group type: EXPERIMENTAL
Intervention: Goal-directed therapy (fluid, with and without dobutamine)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standardised care (control)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Preoperative oxygen delivery achievement (irrespective of intervention)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Goal-directed therapy
Number of subjects: 204
Study: 23697610

Group type: EXPERIMENTAL
Intervention: Low-fat dietary pattern intervention (n = 19,541)
Number of subjects: 48835

Group type: EXPERIMENTAL
Intervention: Low-fat dietary pattern intervention (n = 19,541) among women with higher baseline fat intake
Number of subjects: 48835

Group type: EXPERIMENTAL
Intervention: Low-fat dietary pattern intervention (n = 19,541) among women with lower baseline fat intake
Number of subjects: 48835

Group type: COMPARATOR
Intervention: Comparison group (n = 29,294)
Number of subjects: 48835
Study: 22114899

Group type: EXPERIMENTAL
Intervention: Iscucin® Populi (IP) strength G (0.25%)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Iscucin® Populi (IP) strength H (5%)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Viscum Mali (VM) 2%
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (isotonic solution)
Number of subjects: 71
Study: 18609065

Group type: EXPERIMENTAL
Intervention: Bradykinin (BK) group received 25 microg bradykinin infusion for 7 minutes before cardiopulmonary bypass (CPB)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study: 16978276

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) for 14 weeks
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 97
Study: 14677514

Group type: EXPERIMENTAL
Intervention: Shunted hydrocephalus (HCP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cardiac (control)
Number of subjects: 30
Study: 10996351

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 13
Study: 9388514

Group type: EXPERIMENTAL
Intervention: Combination of chemotherapy and radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early use of radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy and radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induction chemoradiotherapy before surgical resection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy followed by surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of new drugs and radiotherapy
Number of subjects: 0
Study: 2286468

Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (3 g single oral dose)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Pipemidic acid (400 mg twice daily for five days)
Number of subjects: 386
Study: 7013868

Group type: EXPERIMENTAL
Intervention: Chemotherapy protocol combining adriamycin (40 mg/m2 on day 1), vincristine (1.2 mg/m2 on day 2), cyclophosphamide (400 mg/m2 on days 3, 4, 5), 5 fluorouracil (500 mg/m2 on days 3, 4, 5) followed by cyclophosphamide (100 mg/m2/day for 7 days), melphalan (2.5 mg/m2/day for 7 days), methotrexate (25 mg/m2/week for 3 weeks) with 3 applications of living BCG
Number of subjects: 144

Group type: COMPARATOR
Intervention: Chemotherapy protocol without BCG
Number of subjects: 144
Study: 30708074

Group type: EXPERIMENTAL
Intervention: 200 J escalating to 360 J
Number of subjects: 738

Group type: COMPARATOR
Intervention: Fixed 360 J
Number of subjects: 738
Study: 27677853

Group type: EXPERIMENTAL
Intervention: Climate change cue
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Global warming cue
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Implicit cue
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Control (no message)
Number of subjects: 1050
Study: 26546067

Group type: EXPERIMENTAL
Intervention: ACHD-CARE intervention (group psychosocial intervention delivered during eight 90-minute weekly sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 0
Study: 23949834

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 68
Study: 21914905

Group type: EXPERIMENTAL
Intervention: Swim training (DS‐ST) for 12 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (DS‐NT)
Number of subjects: 28
Study: 19170666

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 430

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study: 16449211

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day for 1 week (group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine therapy (group A)
Number of subjects: 40
Study: 15518024

Group type: EXPERIMENTAL
Intervention: Reduced use of third-generation cephalosporins (TGCs) after intervention (April to August 2003)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Reduced use of third-generation cephalosporins (TGCs) after intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: Prior exposure to third-generation cephalosporins (TGCs)
Number of subjects: 88
Study: 11772156

Group type: EXPERIMENTAL
Intervention: Collagenase-containing ointment (Novuxol)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Hydrocolloid dressing (Duoderm)
Number of subjects: 24
Study: 9988985

Group type: EXPERIMENTAL
Intervention: Schizophrenic patients with a history of childhood ADHD
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (schizophrenia only)
Number of subjects: 77
Study: 7942234

Group type: EXPERIMENTAL
Intervention: Orange juice (1 litre daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet and increased fluid intake
Number of subjects: 0
Study: 3281997

Group type: EXPERIMENTAL
Intervention: Ketotifen, 1 mg in the evening during 1 week
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ketotifen, 1 mg, twice daily, during 3 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Salbutamol, 300 micrograms, four times a day
Number of subjects: 19
Study: 29112594

Group type: COMPARATOR
Intervention: Former EPT users
Number of subjects: 13902

Group type: COMPARATOR
Intervention: Former placebo users (for EPT)
Number of subjects: 13902

Group type: COMPARATOR
Intervention: Former ET users
Number of subjects: 13902

Group type: COMPARATOR
Intervention: Former placebo users (for ET)
Number of subjects: 13902
Study: 27855265

Group type: EXPERIMENTAL
Intervention: AVG intervention (Xbox 360), played twice per week for 60 minutes over 12 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 24839883

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) at optimized doses of 30, 50, or 70 mg per day
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study: 23331528

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 100 μg once or twice daily
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 μg once or twice daily
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 127
Study: 20118486

Group type: EXPERIMENTAL
Intervention: eGFRCG (Cockcroft-Gault equation)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: eGFRMC (Mayo Clinic equation)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: eGFRCKD-EPI (Chronic Kidney Disease Epidemiology Collaboration equation)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: eGFRMDRD (Modification of Diet in Renal Disease equation)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Steroid exposure
Number of subjects: 134
Study: 18787325

Group type: EXPERIMENTAL
Intervention: Two-compound scalp formulation (calcipotriol 50 microg/g plus betamethasone dipropionate 0.5 mg/g)
Number of subjects: 869

Group type: COMPARATOR
Intervention: Calcipotriol (50 microg/g)
Number of subjects: 869
Study: 16894800

Group type: EXPERIMENTAL
Intervention: Intensified transition concept (therapeutic weekend care, bedside teaching, structured information for relatives)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard transition
Number of subjects: 70
Study: 12832684

Group type: EXPERIMENTAL
Intervention: Fluticasone 1000 micro g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Beclomethasone 1000 micro g
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10973837

Group type: EXPERIMENTAL
Intervention: Eptifibatide treatment in patients with significant CAD
Number of subjects: 5767

Group type: COMPARATOR
Intervention: Placebo in patients with significant CAD
Number of subjects: 5767

Group type: EXPERIMENTAL
Intervention: Eptifibatide treatment in patients with mild CAD
Number of subjects: 5767

Group type: COMPARATOR
Intervention: Placebo in patients with mild CAD
Number of subjects: 5767

Group type: EXPERIMENTAL
Intervention: Eptifibatide treatment in patients with no CAD
Number of subjects: 5767

Group type: COMPARATOR
Intervention: Placebo in patients with no CAD
Number of subjects: 5767
Study: 8633745

Group type: EXPERIMENTAL
Intervention: Asthma education program for parents
Number of subjects: 3

Group type: COMPARATOR
Intervention: Number of smokers in the family
Number of subjects: 3

Group type: COMPARATOR
Intervention: Perceived adverse impact of asthma on the family
Number of subjects: 3

Group type: COMPARATOR
Intervention: Demographic characteristics, frequency of asthma symptoms, and health care use
Number of subjects: 3

Group type: COMPARATOR
Intervention: Smoking status of parents
Number of subjects: 3
Study: 8267058

Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone supplementation
Number of subjects: 11
Study: 3099944

Group type: EXPERIMENTAL
Intervention: 3 g amoxycillin syrup
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 30067591

Group type: EXPERIMENTAL
Intervention: Heavy-resistance exercise (10 × 5 back squats at 80% one-repetition maximum)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Jumping exercise (10 × 5 jump squats)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Maximal sprinting (15 × 30 m)
Number of subjects: 10
Study: 26903238

Group type: EXPERIMENTAL
Intervention: Auditory processing‐based exercises (40 hours)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Computer games (CG)
Number of subjects: 83
Study: 24373307

Group type: COMPARATOR
Intervention: 8-IM group
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7-IM, 5-IM, 4-IM groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: 8-IM, 5-IM, 4-IM groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: IM group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 dose IM priming schedule
Number of subjects: 0
Study: 23770132

Group type: EXPERIMENTAL
Intervention: Azathioprine (2.5 mg · kg(‐1) · day(‐1))
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 20040914

Group type: EXPERIMENTAL
Intervention: Arbaclofen placarbil (AP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 18950402

Group type: EXPERIMENTAL
Intervention: Mineral oil pretreated side
Number of subjects: 20

Group type: COMPARATOR
Intervention: Emollient-free control side
Number of subjects: 20
Study: 16319477

Group type: EXPERIMENTAL
Intervention: Topical corticosteroid prednicarbat plus wet‐wrap dressing
Number of subjects: 24

Group type: COMPARATOR
Intervention: Topical corticosteroid prednicarbat alone
Number of subjects: 24
Study: 12834495

Group type: EXPERIMENTAL
Intervention: Hexetidine 0.1% mouthwash
Number of subjects: 134

Group type: COMPARATOR
Intervention: Chlorhexidine 0.12% mouthwash (positive control)
Number of subjects: 134

Group type: COMPARATOR
Intervention: 5% hydroalcohol mouthwash (negative control)
Number of subjects: 134
Study: 10830159

Group type: EXPERIMENTAL
Intervention: Explanatory therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waiting list followed by explanatory therapy
Number of subjects: 20
Study: 8841149

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine nasal spray (1 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine nasal spray (1 to 4 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine nasal spray (1 mg) with caffeine (1%)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine nasal spray (1 mg) during vasomotor phenomena
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine nasal spray (1 mg) with fenoxazoline
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine nasal spray (1 mg) during acute viral rhinitis
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine nasal spray
Number of subjects: 9
Study: 1370568

Group type: EXPERIMENTAL
Intervention: Intravenous procaine and low‐molecular‐weight dextran
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 6129077

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Prazosin and Phenoxybenzamine (chronic therapy)
Number of subjects: 11
Study: 31451249

Group type: EXPERIMENTAL
Intervention: 20 ml apple vinegar per day for 8 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no apple vinegar)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Both groups (apple vinegar and control)
Number of subjects: 70
Study: 29512476

Group type: EXPERIMENTAL
Intervention: Wii Fit balance platform
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard customised vestibular rehabilitation protocol
Number of subjects: 40
Study: 26897443

Group type: EXPERIMENTAL
Intervention: Intravenous insulin (regular insulin)
Number of subjects: 202
Study: 22913726

Group type: EXPERIMENTAL
Intervention: Trevo Retriever(TM)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Solitaire Stent(TM)
Number of subjects: 33
Study: 22310061

Group type: EXPERIMENTAL
Intervention: Polyvinyl acetal sponge nasal packing (Merocel)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No nasal packing
Number of subjects: 60
Study: 20432399

Group type: EXPERIMENTAL
Intervention: sc enoxaparin with protocol-mandated IV enoxaparin bolus (0.3 mg/kg)
Number of subjects: 4687

Group type: COMPARATOR
Intervention: sc enoxaparin without protocol-mandated IV enoxaparin bolus
Number of subjects: 4687
Study: 18077136

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 130

Group type: COMPARATOR
Intervention: Clozapine
Number of subjects: 130
Study: 16027621

Group type: EXPERIMENTAL
Intervention: Fränkel appliance therapy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (untreated Class II malocclusion and normal occlusions)
Number of subjects: 78
Study: 12450026

Group type: EXPERIMENTAL
Intervention: Dynamic autoregulatory index (ARI) tests performed every 12 hours during the first 5 days postinjury and daily during the next 5 days
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Cerebral blood flow (CBF) measurements
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Middle cerebral artery blood flow velocity (BFV) measurements
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Cerebrovascular resistance (CVR) measurements
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Comparison of BFV on Day 1
Number of subjects: 122
Study: 10418839

Group type: EXPERIMENTAL
Intervention: Children with spastic diplegic cerebral palsy under compliant foot support with occluded or sway referenced vision
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Children with spastic diplegic cerebral palsy under fixed foot support
Number of subjects: 21

Group type: COMPARATOR
Intervention: Matched controls under compliant foot support with occluded or sway referenced vision
Number of subjects: 21

Group type: COMPARATOR
Intervention: Matched controls under fixed foot support
Number of subjects: 21
Study: 7778318

Group type: EXPERIMENTAL
Intervention: Camonagrel (800 mg orally)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Camonagrel (10 mg/kg i.v.) in cats
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (50 mg/kg i.v.) pretreatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: L-NAME (100 micrograms/kg/min, i.v.) pretreatment
Number of subjects: 0
Study: 2404314

Group type: EXPERIMENTAL
Intervention: Color duplex sonography
Number of subjects: 26

Group type: COMPARATOR
Intervention: Angiography
Number of subjects: 26
Study: 30063644

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg (single dose)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg (single dose)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Nebivolol (weekly administration)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Irbesartan (weekly administration)
Number of subjects: 38
Study: 29054815

Group type: EXPERIMENTAL
Intervention: Whole-brain radiotherapy (WBRT)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Autologous stem-cell transplantation (ASCT)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Comparison of WBRT and ASCT
Number of subjects: 118
Study: 25927718

Group type: EXPERIMENTAL
Intervention: The Virtual Week Training Program - a computerized prospective memory (PM) training program
Number of subjects: 200

Group type: COMPARATOR
Intervention: non-adaptive computer-based word puzzles (active control)
Number of subjects: 200
Study: 23662960

Group type: EXPERIMENTAL
Intervention: Contact Lens Spherical Aberration control
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Vision Training
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 21601352

Group type: EXPERIMENTAL
Intervention: Screening arm (men with interval cancer)
Number of subjects: 42376

Group type: COMPARATOR
Intervention: Control arm (men with PCa)
Number of subjects: 42376
Study: 18645103

Group type: EXPERIMENTAL
Intervention: Multiple-nodal basin drainage
Number of subjects: 2060

Group type: COMPARATOR
Intervention: Single-nodal basin drainage
Number of subjects: 2060
Study: 16445724

Group type: EXPERIMENTAL
Intervention: TTE (transthoracic echocardiography)
Number of subjects: 60

Group type: COMPARATOR
Intervention: x-ray fluoroscopy
Number of subjects: 60
Study: 12952369

Group type: EXPERIMENTAL
Intervention: tibolone 2.5 mg
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol 2 mg plus norethisterone acetate 1 mg (E2/NETA)
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: conjugated equine estrogen 0.625 mg (CEE)
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: CEE/MPA
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: raloxifene HCI 60 mg
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: E2/NETA
Number of subjects: 748

Group type: COMPARATOR
Intervention: non‐users of replacement therapy
Number of subjects: 748
Study: 11075556

Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg.kg‐1
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ketamine 1.0 mg.kg‐1
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lactated Ringer's solution 5 ml (control group)
Number of subjects: 36
Study: 9202366

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 0
Study: 1440804

Group type: EXPERIMENTAL
Intervention: Mefloquine 15 mg/kg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Mefloquine 25 mg/kg
Number of subjects: 85

Group type: COMPARATOR
Intervention: In vitro sensitivity to mefloquine
Number of subjects: 85

Group type: COMPARATOR
Intervention: In vitro sensitivity to chloroquine
Number of subjects: 85
Study: 4041306

Group type: EXPERIMENTAL
Intervention: Procaine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amethocaine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mepivacaine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cinchocaine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lignocaine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Prilocaine
Number of subjects: 10
Study: 31083855

Group type: EXPERIMENTAL
Intervention: Tele-nursing follow-up (phone by nurses for 12 weeks, twice a week for the first month and once a week for the following two months)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tele-nursing follow-up
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (usual follow-up by a specialist)
Number of subjects: 60
Study: 27431234

Group type: EXPERIMENTAL
Intervention: Tribendimidine 25 mg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Tribendimidine 400 mg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Tribendimidine (various doses)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Tribendimidine 200 mg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Tribendimidine (25 to 200 mg)
Number of subjects: 68
Study: 24762684

Group type: EXPERIMENTAL
Intervention: Non-bismuth quadruple therapy for 7 days (esomeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, tinidazole 500 mg given twice daily)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Standard triple therapy for 7 days (esomeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg given twice daily)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Standard triple therapy for 10 days (esomeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg given twice daily)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Non-bismuth quadruple therapy
Number of subjects: 246

Group type: COMPARATOR
Intervention: Standard triple therapy for 7 days
Number of subjects: 246

Group type: COMPARATOR
Intervention: Standard triple therapy for 10 days
Number of subjects: 246
Study: 22356304

Group type: EXPERIMENTAL
Intervention: Formalin dab (4%)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sucralfate-steroid retention enema
Number of subjects: 102
Study: 19778361

Group type: EXPERIMENTAL
Intervention: Whole-body phototherapy
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo light
Number of subjects: 99